How would you approach adjuvant systemic therapy for a patient with a history of localized triple negative breast cancer 7 years prior for which she received adjuvant AC-T, now presenting with another ipsilateral T1cN0 triple negative breast cancer?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Triple negative • University of Wisconsin • NCI-CCC Breast Tumor Board Question

What factors would determine your consideration of this as a recurrence versus a new primary and how would that influence your decision?

Answer from: Medical Oncologist at Community Practice

Although no one can be certain, given that most TNBCs would recur within the 3 to 5-year duration if this was a recurrence from the same clone, would be slim. Based on the CALOR trial, her local recurrence tumor would still benefit from adjuvant or neoadjuvant therapy. Based on the Sharma study, if ...

Comments

Medical Oncologist at Cancer Treatmt Center of America
I agree that there is also data in using a platinu...

Answer from: Medical Oncologist at Community Practice

I would consider weekly carboplatin/paclitaxel based on a recent Phase III adjuvant trial compared with an anthracycline containing regimen in TN breast cancer, showing similar or better efficacy, or consider TC x4-6.

Related Questions